Invention Grant
US09480702B2 Use of chemically modified heparin derivates in sickle cell disease
有权
化学改性肝素衍生物在镰状细胞病中的应用
- Patent Title: Use of chemically modified heparin derivates in sickle cell disease
- Patent Title (中): 化学改性肝素衍生物在镰状细胞病中的应用
-
Application No.: US14366603Application Date: 2012-12-19
-
Publication No.: US09480702B2Publication Date: 2016-11-01
- Inventor: Hans-Peter Ekre , Anna Leitgeb , Mats Wahlgren , Dagmar Pikas
- Applicant: DILAFORETTE AB
- Applicant Address: SE Solna
- Assignee: DILAFORETTE AB
- Current Assignee: DILAFORETTE AB
- Current Assignee Address: SE Solna
- Agency: LeClairRyan, a Professional Corporation
- International Application: PCT/SE2012/051429 WO 20121219
- International Announcement: WO2013/095277 WO 20130627
- Main IPC: C08B37/00
- IPC: C08B37/00 ; A61K31/727 ; A61K45/06
Abstract:
The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
Public/Granted literature
- US20140364369A1 USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE Public/Granted day:2014-12-11
Information query
